Asset Details
Do you wish to reserve the book?
Non-Clinical Safety Studies of IMT504, a Unique Non-CpG Oligonucleotide
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Non-Clinical Safety Studies of IMT504, a Unique Non-CpG Oligonucleotide
Do you wish to request the book?
Non-Clinical Safety Studies of IMT504, a Unique Non-CpG Oligonucleotide
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Non-Clinical Safety Studies of IMT504, a Unique Non-CpG Oligonucleotide
2014
Overview
IMT504 is a non-CpG 24-mer oligodeoxynucleotide (ODN) with immunomodulatory as well as tissue repair activity. IMT504 has been previously proven to be effective in animal models of vaccine potency, chronic lymphocytic leukemia, tissue regeneration, and sepsis. Here, we assessed the safety, including pharmacokinetics and toxicity studies in rats and monkeys, of IMT504 in a single- or repeated-dose administration by the subcutaneous (SC) or intravenous (IV) routes. In rats, the maximum tolerated dose was determined to be 50 mg/kg when administered SC. Adverse effects at 50 mg/kg were mild and reversible liver injury, revealed as lobular inflammation, focal necrosis, and small changes in the transaminase profile. Dose-dependent splenomegaly and lymphoid hyperplasia, most probably associated with immune stimulation, were commonly observed. Rats and monkeys were also IV injected with a single dose of 10 or 3.5 mg/kg, and no adverse effects were observed. Rats injected IV with 10 mg/kg showed a transient increase in spleen weight, together with a slight increase in the marginal zone of the white pulp and in leukocyte count 2 days post-administration. In monkeys, this dosage caused slight changes in total serum complement and leukocyte count on day 14. No adverse effects were observed at 3.5 mg/kg IV in rats or monkeys. Therefore, this dose was defined as the “no observed adverse effect level” for this route. Furthermore, repeated-dose toxicity studies were performed in these species using 3.5 or 0.35 mg/kg/day IV for 6 weeks. A transient increase in the spleen and liver weight was observed at 3.5 mg/kg/day only in female rats. No changes in clotting time and activation of the alternative complement pathway were observed. The toxicity profile of IMT504 herein reported suggests a dose range in which IMT504 can be used safely in clinical trials.
Publisher
Mary Ann Liebert, Inc,SAGE Publications
Subject
/ Animals
/ Cebus
/ Chemical and Drug Induced Liver Injury - etiology
/ Chemical and Drug Induced Liver Injury - pathology
/ Dose-Response Relationship, Drug
/ Drug Administration Schedule
/ Drug Evaluation, Preclinical
/ Female
/ Immunologic Factors - pharmacokinetics
/ Immunologic Factors - toxicity
/ Inflammation - chemically induced
/ Leukemia
/ Male
/ Oligodeoxyribonucleotides - pharmacokinetics
/ Oligodeoxyribonucleotides - toxicity
/ Original
/ Rats
/ Splenomegaly - chemically induced
/ Toxicity
